RESOMER RP d 155 is a methoxy-terminated poly(ethylene glycol)-b-poly(D,L-lactide) diblock copolymer supplied by Evonik Industries for long-acting parenteral drug delivery systems. The product model identifies a diblock architecture in which the 155 designation corresponds to a nominal 15,000 g/mol poly(D,L-lactide) block and a nominal 5,000 g/mol methoxy-poly(ethylene glycol) block, giving a total nominal molecular weight of 20,000 g/mol. This block-size assignment should be confirmed against the current certificate of analysis because minor lot-to-lot variation can occur. The copolymer is used in nanoparticle, microsphere, and injectable depot formulations where a covalently anchored PEG corona is required to modify opsonization, release kinetics, or surface hydrophilicity. Unlike unmodified poly(D,L-lactide-co-glycolide), RP d 155 has no free carboxylic acid terminus at the methoxy-PEG chain end, but the poly(D,L-lactide) segment remains susceptible to hydrolytic ester cleavage.

The specification profile reproduced below is a representative release profile for formulation screening. Batch-specific release values appear on the certificate of analysis and should take precedence.

With a PEG mass fraction of 25 wt%, RESOMER RP d 155 remains water-insoluble but hydrates rapidly at the polymer–water interface. This behavior distinguishes the product from higher-PEG diblock systems that form water-soluble micelles, and from PLGA homopolymers that lack a covalently attached corona. The methoxy terminus is non-ionic, which reduces electrolyte-dependent flocculation expected for acid-terminated polyesters. The poly(D,L-lactide) block is amorphous, so crystallization-induced drug expulsion during storage is less pronounced than with PLLA-containing block copolymers of similar block length.

What Limits the Solvent-Evaporation Window in Microsphere Production?

In a water-in-oil-in-water double-emulsion process, the primary emulsion is generated by dispersing an aqueous drug phase into dichloromethane containing 10–30 wt% RESOMER RP d 155. The methoxy-PEG block migrates to the oil–water interface and lowers interfacial tension. This can aid dispersion, but the 5,000 g/mol PEG segment provides only a mobile steric layer and does not arrest Ostwald ripening as effectively as higher-molecular-weight or more hydrolyzed poly(vinyl alcohol) grades. Rotor-stator processing at 10,000–20,000 min⁻¹ with a 19 mm dispersion head is common for laboratory batches; for pilot-scale work, an inline high-shear mixer with a square-hole screen of 0.5–1.0 mm is preferred because it reduces air incorporation. The critical process window is bounded by two failure modes. High shear or extended mixing causes inner aqueous droplet coalescence and broadens microsphere size distribution; low shear produces a coarse primary emulsion and lowers encapsulation efficiency. The organic phase should remain below 25 °C during initial emulsification to limit dichloromethane vaporization and premature polymer vitrification at the interface. Secondary emulsification into aqueous poly(vinyl alcohol) of 0.1–1.0 wt% with a hydrolysis grade of 75–88 mol% is followed by solvent extraction and hardening. Residual dichloromethane must satisfy the ICH Q3C permitted daily exposure for methylene chloride of 6 mg/day; the dose-proportional limit must be calculated from the intended maximum daily dose. Vacuum post-curing at 20–30 °C and 10–50 mbar is typical, but residual solvent analysis by headspace gas chromatography should be performed on each batch. Microsphere particle-size distribution should be reported as D₁₀, D₅₀, and D₉₀ values by laser diffraction rather than as a single mean diameter.

For sterile microsphere manufacture, the emulsion train is usually maintained in a class C cleanroom with local unidirectional airflow because terminal sterilization of the final microspheres is problematic. Primary emulsion quality should be checked by optical microscopy; primary droplets above 10 µm indicate insufficient shear or premature hardening. Encapsulation efficiency must be measured by a drug-specific validated HPLC method, not by gravimetric polymer recovery alone.

When RESOMER RP d 155 is processed by nanoprecipitation, the copolymer is dissolved in a water-miscible solvent such as acetone or tetrahydrofuran at 5–25 mg/mL and introduced into an aqueous antisolvent under controlled mixing. The methoxy-PEG block orients toward the aqueous phase and forms a non-ionic corona that reduces the need for added surfactant. Particle size depends on solvent-to-non-solvent ratio, feed rate, and antisolvent ionic strength. Narrow distributions are more readily obtained with a confined impinging jet mixer or a syringe-pump-driven microfluidic channel at an aqueous/organic flow-rate ratio of 4:1 to 10:1 than with bulk magnetic stirring. Organic solvent removal is performed by rotary evaporation at 20–30 °C and 50–150 mbar or by tangential-flow filtration. A polyethersulfone cassette with a molecular-weight cut-off of 100–300 kDa can be used for diafiltration and concentration, but membrane compatibility with tetrahydrofuran or acetone must be confirmed before use. The zeta potential of the resulting nanoparticles in 1 mM KCl is commonly between −30 mV and −10 mV; this is less electronegative than acid-terminated PLGA particles and indicates that the methoxy-PEG corona shields carboxylate groups formed by hydrolytic chain scission. Colloidal stability therefore relies primarily on steric repulsion rather than electrostatic repulsion. If the payload is basic, the aqueous antisolvent should be buffered to pH 5.5–7.4 to reduce accelerated ester hydrolysis during solvent stripping. Continuous good-manufacturing-practice nanoprecipitation data for this specific product are limited, so engineering batches must establish the kinetic scope for solvent removal and particle-size reproducibility.

RESOMER RP d 155 can also be evaluated in in situ forming depot systems after dissolution in N-methyl-2-pyrrolidone, dimethyl sulfoxide, or glycofurol. The low total molecular weight of 20,000 g/mol produces lower solution viscosity at equivalent polymer concentration than higher-molecular-weight PLGA, which can reduce injection force. Injectable depot formulations should be characterized for syringeability through a 21G or 23G needle using a texture analyzer at a fixed penetration speed; acceptance must be based on the intended patient population and route of administration. Organic solvent injection routes require biological evaluation according to ISO 10993-1:2018, including local tolerance and systemic toxicity endpoints, because solvent toxicity and irritation are formulation-specific rather than polymer-specific.

Sterile Filtration and Terminal Handling Boundaries for Parenteral Use

Sterile filtration of RESOMER RP d 155 solutions is limited by the viscosity of the polymer solution. In dichloromethane, solutions above 25 wt% can exceed 0.1 Pa·s and reduce flux through a 0.2 µm membrane; a 0.45 µm prefilter is required for aggregates and particulate burden. Membrane compatibility must be confirmed with the selected solvent, and extractable or leachable data are required if the filtered solution enters the final drug product. The dry powder is stored at −20 ± 5 °C under inert gas and should be equilibrated to ambient temperature before opening to avoid condensation. Water uptake above 0.5 wt% measured by Karl Fischer can initiate hydrolytic chain scission during subsequent processing; handling above 60% RH without a dry-air sweep is therefore not recommended. Terminal gamma irradiation at 25–40 kGy may reduce the molecular weight of the poly(D,L-lactide) block and increase acid number by chain scission. Aseptic filtration of the formulated nanosuspension or microsphere intermediate is preferred for moisture-sensitive and low-Tg systems. The diblock should not be dry-blended with strongly basic APIs or amine-containing excipients before dissolution, because alkaline microenvironments accelerate ester hydrolysis and can increase free acid content during storage. Lyophilized formulations containing RP d 155 should be assessed for collapse temperature by freeze-drying microscopy and for residual moisture by Karl Fischer according to USP ⟨921⟩. Reconstitution time, redispersibility, and subvisible particulate counts should be included in the release specification if the product is filled as a sterile powder.

When PEG Coronal Hydration Reduces Burst Without Eliminating Acid-Catalyzed Ester Hydrolysis

With covalent attachment of a 5,000 g/mol PEG block, the diblock changes drug-release behavior relative to unmodified poly(D,L-lactide-co-glycolide) without eliminating bulk erosion. The methoxy-PEG terminus reduces the number of surface-accessible free carboxylic acid end groups, but the poly(D,L-lactide) segment still hydrolyses to lactic acid and oligomeric acids. Microclimate pH values below 4 have been reported for degrading polyester microparticles under stagnant conditions, and this can accelerate further chain scission and damage acid-labile payloads. Compared with acid-terminated PLGA grades such as RESOMER RG 503 H, RP d 155 provides a covalently anchored surface layer that cannot desorb during media exchange; this can reduce initial burst for proteins or peptides, but the degree depends on drug log P and payload solubility in the release medium. Compared with physically adsorbed poloxamer or polysorbate, the covalent PEG corona persists through centrifugation and washing steps. Compared with triblock PEG-PLGA-PEG, the single PEG segment lowers the tendency to form bridged micellar networks at physiological temperature, which reduces thermoreversible gelling behavior and may improve batch-to-batch reproducibility in nanoprecipitation but restricts use as an in situ gelling system. Compared with PLLA-PEG of similar block length, the D,L-lactide configuration avoids crystallization of the polyester block and minimizes crystalline drug expulsion during storage. Formulators evaluating this product should generate in-house in vitro release profiles under sink conditions, using USP apparatus 4 or a sample-and-separate method with a release medium volume sufficient to maintain sink capacity for the payload. The dissolution test should be paired with gel-permeation chromatography to measure molecular weight loss and with ultra-performance liquid chromatography to quantify residual monomer and degradation products. Published comparative release data for this specific product code are limited; therefore, generic comparisons to PLGA should not replace batch-specific characterization in the intended dosage form.